Online inquiry

IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11771MR)

This product GTTS-WQ11771MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11771MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9331MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ4191MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ7531MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ10180MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ9689MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ4039MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ11055MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCLA-158
GTTS-WQ11458MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-9447
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW